Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

Table 1 Antiemetic regimens in each study

Antiemetic		Day 1	Day 2	Day 3	Day 4
Study 1
5HT₃RA	i.v.	※
Aprepitant	p.o.	125 mg	80 mg	80 mg
Dexamethasone*	i.v.	4.95 mg
Olanzapine	p.o.	5 mg	5 mg	5 mg	5 mg
Study 2
Granisetron	i.v.	1 mg
Aprepitant	p.o.	125 mg	80 mg	80 mg
Dexamethasone** or Dexamethasone	p.o.	12 mg
Dexamethasone** or Dexamethasone	i.v.	9.9 mg
Olanzapine	p.o.	5 mg	5 mg	5 mg	5 mg
Study 3
Granisetron	i.v.	1 mg
Dexamethasone ** or Dexamethasone	p.o.	12 mg	8 mg	8 mg
Dexamethasone ** or Dexamethasone	i.v.	9.9 mg	6.6 mg	6.6 mg
Olanzapine	p.o.	5 mg	5 mg	5 mg	5 mg

Dexamethasone 3.3 mg i.v. = 4 mg p.o.
※Granisetron: 1 or 3 mg, palonosetron: 0.75 mg, ramosetron: 0.3 mg.
*When paclitaxel is used, 9.9 or 12 mg DEX is, respectively, administered intravenously or orally on day 1
**When more than 135 mg/m² paclitaxel is used, 19.8 or 20 mg DEX is, respectively, administered intravenously or orally on day 1
5-HT₃RA 5-hydroxytryptamine-3 receptor antagonist.

ISSN: 1471-2407